The FDA's newly released guidance emphasizes the need for additional clinical trials before approving vaccines for healthy adults and children. This decision, articulated by FDA officials, raises concerns about accessibility to important COVID-19 vaccines, especially as many experts believe it is too restrictive. Critics argue that the one-size-fits-all approach in the US contrasts with European strategies focused on high-risk groups, suggesting a policy shift that reflects political influences impacting vaccine regulations and public health strategies.
This is overly restrictive and will deny many people who want to be vaccinated a vaccine.
The FDA's new COVID-19 philosophy represents a balance of regulatory flexibility and a commitment to gold-standard science.
The policy shift reflects the Trump administration's open hostility towards vaccines, led by figures like Robert F. Kennedy Jr.
European nations typically confine vaccine recommendations to older adults and those at severe COVID risk.
Collection
[
|
...
]